Currently, PD-1/PD-L1 blockade has become a backbone for the treatment in advanced NSCLC patients without driver mutations.34,35 Meanwhile, several studies attempted to evaluate the efficacy of PD-1/PD-L1 blockade monotherapy in NSCLC patients with EGFR mutations, either at the frontline setting in PD-L1 high-expression population or at later line setting after the failure of EGFR-TKI.36,37 All of them led to disappointing results. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.